e-Drug3D
1483
ROMIDEPSIN
INN
ROMIDEPSIN
cas 128517-07-7
CLASS
ANTINEOPLASTIC
HISTONE DEACETYLASE (HDAC) INHIBITOR
CUTANEOUS T-CELL LYMPHOMA (CTCL)
ROUTE (list)
INTRAVENOUS
ATC code
L01XH02
PK parameters
VD 78 LITER (65 KILOGRAM)
Cl 28.8 LITER / HOUR (65 KILOGRAM)
PPB 93 PERCENT
t1/2 3 HOUR (14 MILLIGRAM / M2)
TARGET HISTONE DEACETYLASE (IC50 NANOMOLAR RANGE)
Histone deacetylase UNIPROT O15379 HDAC3
Formula:
C24H36N4O6S2
Calculated chemical properties:
MW 540.71
NB_atoms 36
XLogP 1.43
PSA 91.152
NB_HD 4
NB_HA 10
fsp3 0.62
Lipinski(0=no;1=yes) 0
NB_atoms 36
XLogP 1.43
PSA 91.152
NB_HD 4
NB_HA 10
fsp3 0.62
Lipinski(0=no;1=yes) 0
FDA
NDA 022393 (label) INN (ROMIDEPSIN) ISTODAX (BRISTOL-MYERS) APPROVAL= AP YEAR= 2009 NEWMOLECULARENTITY
NDA 208574 (label) INN (ROMIDEPSIN) ROMIDEPSIN (TEVA PHARMS USA INC) APPROVAL= AP YEAR= 2020 DISCONTINUED
NDA 206254 (pdf not found) INN (ROMIDEPSIN) ROMIDEPSIN (FRESENIUS KABI USA) APPROVAL= AP YEAR= 2021
NDA 219099 (pdf not found) INN (ROMIDEPSIN) ROMIDEPSIN (AMNEAL) APPROVAL= AP YEAR= 2026
NDA 022393 (label) INN (ROMIDEPSIN) ISTODAX (BRISTOL-MYERS) APPROVAL= AP YEAR= 2009 NEWMOLECULARENTITY
NDA 208574 (label) INN (ROMIDEPSIN) ROMIDEPSIN (TEVA PHARMS USA INC) APPROVAL= AP YEAR= 2020 DISCONTINUED
NDA 206254 (pdf not found) INN (ROMIDEPSIN) ROMIDEPSIN (FRESENIUS KABI USA) APPROVAL= AP YEAR= 2021
NDA 219099 (pdf not found) INN (ROMIDEPSIN) ROMIDEPSIN (AMNEAL) APPROVAL= AP YEAR= 2026